Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wang T, Quijada D, Ahmedna T, Castillo JR, Naji NS, et al.
Tuberculosis (TB) remains among the leading infectious causes of death. Due to the limited number of antimicrobials in the TB drug discovery pipeline, interest has developed in host-directed approaches to improve TB treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) …
Brendan M Crowley, Helena I Boshoff, Aidan Boving, Vee Y Tan, Jianghai Zhu, et al.
…cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK…
Brandenburg J, Heyckendorf J, Marwitz F, Zehethofer N, Linnemann L, et al.
… estimated to be infected with strains of the Mycobacterium tuberculosis complex (MTBC), the causative agent of tuberculosis (TB). Using lipidomic approaches, we show that tuberculostearic acid (TSA)-containing phosphatidylinositols (PIs) are molecular markers for infection with …
Salindri AD, Sales RF, DiMiceli L, Schechter MC, Kempker RR, et al.
Rationale Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear. Objectives This study aims to understand 1) factors associated with INH-monoresistant T…
Min J, Chung C, Jung SS, Park HK, Lee SS, et al.
Background Subclinical tuberculosis (TB) is a potential target for public health intervention because its early identification may reduce TB transmission. We aimed to describe the clinical and laboratory findings of subclinical disease among pulmonary TB patients and compared tre…
Yasobant S, Shah H, Bhavsar P, Patel J, Saha S, et al.
Tuberculosis (TB) is the second leading cause of death due to infectious diseases globally, and delay in the TB care cascade is reported as one of the major challenges in achieving the goals of the TB control programs. The main aim of this study was to investigate the delay and r…
Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, et al.
Background Excellent adherence to tuberculosis (TB) treatment is critical to cure TB and avoid the emergence of resistance. Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and pair…
Calderwood CJ, Wilson JP, Fielding KL, Harris RC, Karat AS, et al.
…y recommended for people commencing treatment for pulmonary tuberculosis (TB). The evidence that this corresponds to clearance of potentially infectious tuberculous mycobacteria in sputum is not well established. This World Health Organization-commissioned review investigated spu…
Walter ND, Moore CM, Kayigire XA, Dide-Agossou C, Worodria W, et al.
Background According to the traditional tuberculosis (TB) treatment paradigm, the initial doses of treatment rapidly kill most Mycobacterium tuberculosis (Mtb) bacilli in sputum, yet many more months of daily treatment are required to eliminate a small, residual subpopulation of …
Ang MLT, Chan SM, Cheng LT, Cheong HY, Chew KL, et al.
Introduction Tuberculosis (TB) remains endemic in Singapore. Singapore's clinical practice guidelines for the management of tuberculosis were first published in 2016. Since then, there have been major new advances in the clinical management of TB, ranging from diagnostics to new …
Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H, et al.
… treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach thi…
Fatima S, Bhaskar A, Dwivedi VP
Tuberculosis (TB) is an infectious disease caused by an obligate intracellular pathogen, Mycobacterium tuberculosis (M.tb) and is responsible for the maximum number of deaths due to a single infectious agent. Current therapy for TB, Directly Observed Treatment Short-course (DOTS)…
Mbano IM, Mandizvo T, Rogich J, Kunota TTR, Mackenzie JS, et al.
…ckground There is a well-documented lack of rapid, low-cost tuberculosis (TB) drug resistance diagnostics in low-income settings across the globe. It is these areas that are plagued with a disproportionately high disease burden and in greatest need of these diagnostics. Methods I…
Oladimeji O, Adepoju V, Anyiam FE, San JE, Odugbemi BA, et al.
Background The Lagos State Tuberculosis, Buruli Ulcer, and Leprosy Control Program (LSTBLCP) started engaging private hospitals under the Public-Private Mix (PPM) Program in 2008. The study aimed to evaluate the trend and predictors of successful Tuberculosis (TB) treatment outco…
Tudó G, Lopez-Gavin A, Portell-Buj E, Freixes J, Vila J, et al.
…loxacin (LFX), and moxifloxacin (MOX) against Mycobacterium tuberculosis isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. …
Nie W, Wang J, Zeng J, Wang Q, Du Y, et al.
…acy and safety of IL-2 in the treatment of drug-susceptible tuberculosis. Methods First, the cases of diagnosed drug-susceptible tuberculosis were randomized into two groups-the control group that received the background regimen of isoniazid, rifampin, pyrazinamide, and ethambuto…
M Olugbosi, M Beumont, L Lombard, J Nedelman, J Timm, et al.
**INTRODUCTION:** In 2023, tuberculosis (TB) returned to being the world's leading cause of death from a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes and increased…
Huang CK, Yu MC, Hung CS, Lin JC
…n the treatment of both drug-susceptible and drug-resistant tuberculosis, but its use is challenged by the reliability of drug-susceptibility testing (DST). PZA resistance in Mycobacterium tuberculosis (MTB) is relevant to the amino acid substitution of pyrazinamidase that is res…
Oh AL, Makmor-Bakry M, Islahudin F, Ting CY, Chan SK, et al.
Background Tuberculosis (TB) treatment interruption poses risks of antimicrobial resistance, potentially leading to treatment failure and mortality. Addressing the risk of early treatment interruption is crucial in tuberculosis care and management to improve treatment outcomes an…
John Kauffman, Jake Cuevas, Janaya Feiner, Margaret Metzger, Gauri Shetye, et al.
There is an urgent need to develop new anti-tuberculosis (anti-TB) drugs to tackle drug-resistant strains of Mycobacterium tuberculosis (M.tb). Whereas antimicrobial peptides (AMPs) have received attention because of their antibacterial properties, oligo-N-substituted glycines (p…
Reza Yosofi A, Mesic A, Decroo T
Background Treatment for rifampicin-resistant tuberculosis (RR-TB) has been shortened to 12 months or less, with duration depending on the regimen used and treatment response. Treatment shortening has the potential to increase the risk of relapse, with a new episode of RR-TB afte…
Ananthi Rajendran, Ahmed Kabir Refaya, Kannan Palaniyandi
**AIMS:** Pyrazinamide (PZA) resistance in Mycobacterium tuberculosis challenges tuberculosis management, primarily through pncA mutations, while broader transcriptional adaptations remain unclear. This study aimed to characterize the transcriptomic adaptations associated with PZ…
Ridolfi F, Peetluk L, Amorim G, Turner M, Figueiredo M, et al.
Background Successful tuberculosis (TB) treatment is necessary for disease control. The World Health Organization (WHO) has a target TB treatment success rate of ≥90%. We assessed whether the different types of unfavorable TB treatment outcome had different predictors. Methods Us…
Moon CW, Porges E, Taylor SC, Bacon J
…onent of chemotherapy for the treatment of drug-susceptible tuberculosis (TB) and is likely to continue to be included in new drug combinations. Potentiation of PZA could be used to reduce the emergence of resistance, shorten treatment times, and lead to a reduction in the quanti…
Byonanebye DM, Mackline H, Sekaggya-Wiltshire C, Kiragga AN, Lamorde M, et al.
Background Throughout the last decade, tuberculosis (TB) treatment success has not surpassed 90%, the global target. The impact of mobile health interventions (MHIs) on TB treatment outcomes is unknown, especially in low- and middle-income countries (LMICs). MHIs, including inter…